



SHEET 1 of 1

Form PTO-141 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
6248.4Serial No.
09/599,213

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicants
Erik H.F. Wong et al.

RECEIVED

Filing Date
June 22, 2000

Group APR 11 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS


*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
DRS		2,014,981	09/05/79	Great Britain				
		WO 99/52531	10/21/99	PCT				
		WO 99/52518	10/21/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

DRS	E. Frigerio et al., <i>Pharmacokinetics of Reboxetine Enantiomers in the Dog</i> , Chirality, Vol. 9, pp. 303-06 (1997).
DRS	G.D. Burrows et al., <i>Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review</i> , J. Clin. Psychiatry, Vol. 59, Suppl. 14, 4 pages (1998).

::ODMA\PCDOCS\DOCS\490205\1

EXAMINER	WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED 10/5/01
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



JUL 20 2001

U.S. Department of Commerce
Patent and Trademark Office

SHEET 1 of 2

TOP

S

Serial No.
09/599,213Atty. Docket No.
6248.4

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED

JUL 23 2001
C E N T E R 1600/200

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
WJ		WO 99/20279	04-29-99	PCT	1	1		
		WO 99/58130	11-18-99	PCT				
		WO 01/26623	04-19-01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

2001		B.E. Leonard, <i>Noradrenaline in Basic Models of Depression</i> , European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S11-S16 (1997).
		Discussion, European Neuropsychopharmacology, Vol. 7, Suppl. 1, pp. S71 (1997).
		D. Healy et al., <i>The Clinical Pharmacologic Profile of Reboxetine: Does it Involve the Putative Neurobiological Substrate of Wellbeing?</i> , J. of Affective Disorders, Vol. 51, pp. 313-22 (1998).
		Anonymous, <i>Reboxetine - Another New Antidepressant</i> , Drugs and Therapeutics Bull., 36 (11) (Nov. 1998).
		S.A. Montgomery, <i>The Place of Reboxetine in Antidepressant Therapy</i> , J. of Clinical Psychiatry, Vol. 59, Suppl. 14, pp. 26-29 (1998).
✓		G.D. Burrows et al., <i>Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review</i> , J. Clin. Psychiatry, Vol. 59, Suppl. 14, 4 pages (1998).

EXAMINER	WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED
DD/5/01		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

O I P E
U.S. Patent and Trademark Office

JUL 20 2001

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 6248.4	Serial No. 09/599,213
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicants Erik H.F. Wong et al.	JUL 23 2001 TER 16002600
		Filing Date June 22, 2000	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

<i>ASJ</i>	S. Kasper, <i>From Symptoms to Social Functioning: Differential Effects of Antidepressant Therapy</i> , International Clinical Psychopharmacology, Vol. 14, Suppl. 1, pp. S27-S31 (May 1999).
	International Search Report in PCT/US00/17256 dated July 12, 2001.

@PFDesktop\::ODMA/PCDOCS/DOCS/511298/1

EXAMINER	WILLIAM R. A. JARVIS PRIMARY EXAMINER	DATE CONSIDERED <i>10/15/01</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		